Immunochemotherapy in advanced neuroblastoma
- 1 April 1978
- Vol. 41 (4) , 1282-1288
- https://doi.org/10.1002/1097-0142(197804)41:4<1282::aid-cncr2820410411>3.0.co;2-h
Abstract
Twenty-two children with advanced (Stage III and IV) neuroblastoma have been treated in a nonrandomized fashion, half with a three-drug regimen consisting of vincristine, adriamycin, and cyclophosphamide, and half with this same drug combination plus the nonspecific immunostimulatory agent, MER/ BCG. The addition of MER to the three-drug combination appeared to improve the duration of survival in this pilot study. The median duration of response was less than one year in the combination chemotherapy alone arm. The median duration of complete remission in children treated with the addition of MER has yet to be reached at 24 months.This publication has 7 references indexed in Scilit:
- MER and Other Mycobacterial Fractions in the Immunotherapy of CancerMedical Clinics of North America, 1976
- Lymphocyte-Mediated Cytotoxicity And Blocking Serum Activity To Tumor AntigensPublished by Elsevier ,1974
- Treatment of neuroblastomaCancer, 1972
- A proposed staging for children with neuroblastoma.Children's cancer study group ACancer, 1971
- Demonstration of cell-bound and humoral immunity against neuroblastoma cells.Proceedings of the National Academy of Sciences, 1968
- Combination Chemotherapy of Childhood NeuroblastomaJAMA, 1965
- NITROGEN MUSTARD THERAPYJAMA, 1946